Figure 1. Potential applications of Skp2 inhibitor compound #25. The current study identifies a specific Skp2 inhibitor compound #25 that phenocopies the effect of Skp2 deficiency to target tumorigenesis by upregulation of p27 tumor suppressor and inactivation of Akt oncoprotein. Given that Skp2 loss reduces the number of adipocytes, possibly through p27 accumulation, compound #25 may also be used as a tool for obesity prevention.